Key takeaways
- Melanotan 2 is a seven-amino-acid, ring-shaped analogue of α-MSH; in a 1997 cell study it bound the human MC1, MC3, MC4 and MC5 melanocortin receptors.
- It is not afamelanotide (Scenesse), an approved medicine for adults with erythropoietic protoporphyria, and not bremelanotide (PT-141), which was developed from it and is the active ingredient of Vyleesi, a US prescription medicine; products sold online as “PT-141” are not that medicine.
- FDA’s compounding page cites published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism; the TGA warns of the risk of serious skin cancers.
- In August 2026 the TGA reported inconsistent amounts of melanotan II in five seized nasal sprays carrying the same label, and 27 infringement notices for alleged unlawful supply.
- Australia lists it in Schedule 4 (prescription only); the MHRA says it has acted for over 10 years to remove melanotan products that count as medicines from the UK market.
01Melanotan 2 at a glance
The short version, dated 18 November 2026.
| Question | Melanotan 2 |
|---|---|
| What it is | A synthetic peptide of seven amino acids, six of them closed into a ring: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. An analogue of alpha-melanocyte-stimulating hormone (α-MSH). |
| Other names | Melanotan II, MT-II. Not the same as melanotan I (afamelanotide). |
| Receptor targets | In a 1997 cell study it bound the human MC1, MC3, MC4 and MC5 receptors. |
| Evidence on harms | T2: case reports and regulators’ adverse-event summaries. |
| United States | Not approved. FDA has considered it an unapproved new drug since at least 2007. |
| European Union | No EU-wide authorisation: no melanotan II medicine in the EMA’s data on centrally authorised medicines (17 Nov 2026). |
| United Kingdom | The MHRA classes injectable and pen products as medicines and says it has acted for over 10 years to remove melanotan products that count as medicines (April 2024). |
| Australia | Schedule 4 (prescription only) in the Poisons Standard October 2026. The TGA says no product containing it is included in the ARTG or approved for supply. |
| WADA | Not named on the 2026 or 2027 Prohibited List; check with your anti-doping organisation. |
02What is melanotan 2?
Melanotan 2 is another way of writing melanotan II (MT-II), a synthetic peptide. A 1996 paper from the University of Arizona describes it as a cyclic heptapeptide analogue of α-MSH: seven amino acids, with a lactam bridge that closes six of them into a ring.
Melanocortin receptors come in five types, MC1R to MC5R. In a 1997 study in cells engineered to carry human receptors, melanotan II bound MC1R, MC3R, MC4R and MC5R (T4: binding in cells, not effects in people). According to the bremelanotide label, MC1R is found on melanocytes, the skin’s pigment cells, and MC4R on nerve cells in many areas of the brain and spinal cord.
This page describes what melanotan II binds and what regulators have recorded about it. How we grade evidence: evidence grades.
03How does melanotan 2 differ from afamelanotide and bremelanotide?
Three related peptides are often confused. Two are approved medicines, each for one use. Melanotan II is not.
| Melanotan II | Afamelanotide | Bremelanotide (PT-141) | |
|---|---|---|---|
| Structure | 7 amino acids, ring-shaped, amide end | 13 amino acids in a chain, an analogue of α-MSH | 7 amino acids, the same ring as melanotan II, free-acid end |
| Other names | MT-II | Scenesse; cross-referenced as melanotan I in Australia’s Poisons Standard | Vyleesi |
| Receptors | Bound MC1R, MC3R, MC4R and MC5R in a cell study | Binds mainly MC1R (label) | Activates several subtypes, most potently MC1R, then MC4R (label) |
| Approved? | No (US, Australia); no EU-wide authorisation | EU 2014, US 2019 | US 2019 |
| Approved use | None | Adults with erythropoietic protoporphyria (EPP) who have had phototoxic reactions | One diagnosed condition in premenopausal women |
| Skin warning on the label | No label | May darken existing moles and freckles; full-body skin checks twice a year recommended | Dark patches on the face, gums or breasts in 1% of phase 3 participants, none on placebo, and in 38% in a separate study with more frequent use; more likely with darker skin; fading not confirmed in all |
Products sold as melanotan II are neither of the approved medicines, and products sold online as “PT-141” are not Vyleesi. More on bremelanotide: PT-141 (bremelanotide).
04What adverse events have been reported with melanotan 2?
Events documented in people who used products sold as melanotan, regulators’ summaries of them, and those recorded in one small early study. Apart from that study, they come from reports, not controlled trials.
- FDA. Its compounding page says that compounded melanotan II “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities”, and that “Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.” In plain terms: immunogenicity is the risk of an immune reaction to the peptide, and the last three events are a form of brain swelling, over-stimulation of the nervous system, and a prolonged erection.
- TGA (January 2025). “While the most common side effects include headache, nausea, vomiting, loss of appetite, and facial redness, the most concerning one is the risk of serious skin cancers. With melanotan-II, there have been reports of increased moles and freckles, kidney dysfunction and swelling of the brain.”
- Moles and melanoma. A 2017 review of case reports on melanotan I and II found reports of changes in existing moles and of new, sometimes atypical (dysplastic) moles, and four case reports of melanomas arising from existing moles during or shortly after use. The authors wrote that conclusive evidence linking these events to melanotan is lacking.
- UK reports. The MHRA received 16 UK suspected adverse drug reaction reports for melanotan II between 2012 and 2022. It notes that a report “does not necessarily mean that the events were caused by the product”, and that its scheme has “an unknown and variable level of reporting”.
- Early study. In the 1996 pilot study, in 3 men over two weeks, mild nausea was recorded, and grade II sleepiness and fatigue in one participant.
Case reports show that an event happened after use. They cannot show how often it happens or, on their own, prove what caused it. How to read reports like these: side effects, documented vs unknown.
05What have regulators done about melanotan 2?
Australia. On 17 August 2026 the TGA said it had seized products suspected to contain melanotan II, and that its laboratory had confirmed the substance in them. Five seized nasal spray bottles with the same label held an estimated 73% to 180% of the labelled amount (our calculation from the TGA’s figures), and the TGA said the inconsistency “further increases the chance of adverse events”. It reported 27 infringement notices, totalling A$101,412 and paid in May 2026, issued to a New South Wales individual for the alleged unlawful supply of melanotan II. The TGA says melanotan II “is a prescription-only medicine in Australia and is not approved for use as a tanning agent”. More: are peptides legal in Australia?
United States. In August 2007 FDA sent a warning letter to a US company selling melanotan II, stating that, based on the company’s website, it was a new drug that could not be sold without an approved application. According to FDA’s 2016 notice, the company kept shipping it; its owner pleaded guilty in 2015 to conspiracy, and FDA proposed a permanent debarment. FDA’s Import Alert 66-41 lists melanotan I and II products from three named firms, in entries dated 2010 to 2019 (alert version published 17 November 2026); the entries for two of them note that the product was imported for non-human research and then “the unapproved new drug is sold on internet”. FDA’s compounding page lists melanotan II among substances “previously in category 2” whose nominations “were withdrawn by the nominators”, and keeps the risk statements quoted above. How FDA handles such products at the border: peptides, customs and import.
United Kingdom. In April 2024 the MHRA said products containing melanotan II are classed as medicines if they are injectable or pens, and a nasal spray only if it is sold with claims to treat or prevent disease. It said “the sale, supply and advertising of unauthorised medicines is not permitted under the Human Medicines Regulations”, and that it “has repeatedly taken action to remove Melanotan products from the market for over 10 years”, where products fall within the definition of a medicine. More: are peptides legal in the UK?
Sport. Melanotan II is not named on WADA’s 2026 or 2027 Prohibited List. The List’s S0 class covers substances with “no current approval by any governmental regulatory health authority for human therapeutic use”, and anti-doping organisations decide how it applies. See peptides and anti-doping.
06What we don’t know
- How often the reported events happen. Case reports and the MHRA’s report counts cannot give a rate.
- Whether melanotan II causes melanoma. The 2017 review found conclusive evidence lacking; the TGA warns of the risk of serious skin cancers.
- What a given product contains. The TGA found inconsistent amounts across five bottles with the same label.
- Its long-term effects. The published clinical studies we found are small and short, such as the 1996 pilot study of 3 men over two weeks (PubMed, 18 Nov 2026). A placebo-controlled phase 2 trial registered in February 2026 has posted no results (ClinicalTrials.gov NCT07437560, 18 Nov 2026).
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.